Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Mallinckrodt
Dow
Merck
Medtronic

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,727,954

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,727,954
Title:Drug depot implant designs
Abstract: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.
Inventor(s): McKay; William F. (Memphis, TN)
Assignee: Warsaw Orthopedic, Inc. (N/A)
Application Number:11/734,618
Patent Claims:1. A drug depot implant comprising: a body having a surface and opposites sides; an anchoring system extending from the body, the anchoring system comprising at least two angled flexible barbs, each of the at least two angled flexible barbs comprising a point adapted to allow forward translational movement of the body and limit backward translational movement of the body from a targeted tissue, wherein the at least two angled flexible barbs are on the surface of the body and the at least two angled flexible barbs are located on opposite sides of the body; and a therapeutic agent comprising a NFkB inhibitor disposed throughout the body and the anchoring system, wherein the body and the anchoring system are capable of eluting the therapeutic agent and the drug depot implant is solid and provides an optimal concentration of the therapeutic agent from 1 cm to 5 cm from the drug depot implant.

2. The drug depot implant of claim 1 wherein the anchoring system provides a surface adapted to abut against a tissue plane.

3. The drug depot implant of claim 2 wherein the anchoring system further comprises an end cap disposed on an end of the body of the drug depot implant.

4. The drug depot implant of claim 1 wherein the anchoring system further comprises a suture.

5. The drug depot implant of claim 1 further comprising a radiographic marker adapted to assist in radiographic imaging of the drug depot implant.

6. The drug depot implant of claim 5 wherein the radiographic marker is selected from the group consisting of barium, calcium phosphate, and metal beads.

7. The drug depot implant of claim 1 wherein the body is formed from a biodegradable material.

8. The drug depot implant of claim 7 further comprising a plurality of microspheres disposed in the biodegradable material, the microspheres encapsulating at least a portion of the therapeutic agent.

9. The drug depot implant of claim 1 wherein the body and anchoring system are biodegradable.

10. The drug depot implant of claim 1 wherein the targeted tissue site is a synovial joint.

11. The drug depot implant of claim 1 wherein the targeted tissue site is a soft tissue.

12. The drug depot implant of claim 11 wherein the soft tissue is selected from the group consisting of muscle, ligament, tendon, and cartilage.

13. The drug depot implant of claim 1 wherein the targeted tissue site is a disc.

14. The drug depot implant of claim 1, wherein the NFkB inhibitor is an anti-inflammatory agent and the drug depot implant further comprises at least one additional anti-inflammatory agent, which is selected from the group consisting of soluble tumor necrosis factor .alpha. receptors, pegylated soluble tumor necrosis factor .alpha. receptors, monoclonal antibodies, polyclonal antibodies, antibody fragments, COX-2 inhibitors, metalloprotease inhibitors, such as TAPI, glutamate antagonists, glial cell derived neurotrophic factors (GDNF), B2 receptor antagonists, Substance P receptor (NK1) antagonists, Downstream regulatory element antagonistic modulator (DREAM), iNOS, inhibitors of tetrodotoxin (TTX)-resistant Na+-channel receptor subtypes PN3 and SNS2, inhibitors of interleukins, such as IL-1, IL-6, IL-8 and IL-10, TNF binding protein, dominant-negative TNF variants, Nanobodies.TM., kinase inhibitors, Adalimumab, Infliximab, Etanercept, Pegsunercept (PEG sTNF-R1), Onercept, Kineret.RTM., sTNF-R1, CDP-870, CDP-571, CNI-1493, RDP58, ISIS 104838, 1.fwdarw.3-.beta.-D-glucans, Lenercept, PEG-sTNFRII Fc Mutein, D2E7, Afelimomab, AMG 108, 6-methoxy-2-napthylacetic acid) or betamethasone, capsaiein, civanide, TNFRc, ISIS2302 and GI 129471, integrin antagonists, alpha-4 beta-7 integrin antagonists, cell adhesion inhibitors, interferon gamma antagonists, CTLA4-Ig agonists/antagonists (BMS-188667), CD40 ligand antagonists, Humanized anti-IL-6 mAb (MRA, Tocilizumab, Chugai), HMGB-1 mAb (Critical Therapeutics Inc.), anti-IL2R antibody (daclizumab, basilicimab), ABX (anti IL-8 antibody), recombinant human IL-10, HuMax IL-15 (anti-IL 15 antibody), NF Kappa B inhibitors, glucocorticoids, clonidine, nonsteroidal anti-inflammatory drugs (NSAIDs), sulindac and tepoxalin, antioxidants, dithiocarbamate, sulfasalazine [2-hydroxy-5-[-4-[C2-pyridinylamino)sulfonyl]azo]benzoic acid], and flucinolone, and combinations thereof.

15. The drug depot implant of claim 4 wherein beads are linearly disposed along the suture.

16. A solid drug depot implant comprising: a rod-shaped body having a surface and opposite sides; an anchoring system extending from the rod-shaped body, the anchoring system adapted to limit movement of the rod-shaped body from a targeted tissue, the anchoring system comprising at least four barbs on the surface of the rod-shaped body, a first pair of the at least four barbs located on opposite sides of the rod-shaped body, each barb of the first pair comprising a point adapted to limit backward movement of the body from a targeted tissue and a second pair of the at least four barbs located on opposites sides of the rod-shaped body, each barb of the second pair comprising a point adapted to limit forward movement of the body from a targeted tissue; and a therapeutic agent comprising a NFkB inhibitor disposed throughout the rod-shaped body and the anchoring system, wherein the rod-shaped body and anchoring system are capable of eluting the therapeutic agent.

17. A solid drug depot implant according to claim 16, wherein the anchoring system comprises flexible barbs and the flexible barbs snap on the rod-shaped body.

Details for Patent 7,727,954

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Warsaw Orthopedic, Inc. ( 2026-04-13 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Warsaw Orthopedic, Inc. ( 2026-04-13 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Warsaw Orthopedic, Inc. ( 2026-04-13 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Warsaw Orthopedic, Inc. ( 2026-04-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKesson
Boehringer Ingelheim
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.